Sequenom Posts 28 Percent Increase in Q4 Revenues as SEC Wraps up Investigation

The company's CEO said that SEC staff has told the firm that the agency may bring civil injunction action against Sequenom, "alleging that we violated certain anti-fraud and books of record" infractions.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories